ClinicalTrials.gov record
Tiotropium / Respimat One Year Study in COPD.
ClinicalTrials.gov ID: NCT00387088
Public ClinicalTrials.gov record NCT00387088. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.
Study identification
- NCT ID
- NCT00387088
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 3,991 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2006 (Type not available)
- Primary completion
- Jan 2009 (Actual)
- Completion
- Not listed
- Last update posted
- May 16, 2014
Started 2006
United States locations
- U.S. sites
- 57
- U.S. states
- 26
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.372.01012 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 205.372.01020 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 205.372.01062 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 205.372.01048 Boehringer Ingelheim Investigational Site | Berkeley | California | — | — |
| 205.372.01037 Boehringer Ingelheim Investigational Site | Huntington Park | California | — | — |
| 205.372.01058 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 205.372.01059 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 205.372.01007 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 205.372.01034 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 205.372.01028 Boehringer Ingelheim Investigational Site | Rancho Mirage | California | — | — |
| 205.372.01011 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 205.372.01066 Boehringer Ingelheim Investigational Site | Boulder | Colorado | — | — |
| 205.372.01008 Boehringer Ingelheim Investigational Site | Norwalk | Connecticut | — | — |
| 205.372.01004 Boehringer Ingelheim Investigational Site | Brandon | Florida | — | — |
| 205.372.01060 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 205.372.01069 Boehringer Ingelheim Investigational Site | Miami Beach | Florida | — | — |
| 205.372.01023 Boehringer Ingelheim Investigational Site | West Palm Beach | Florida | — | — |
| 205.372.01053 Boehringer Ingelheim Investigational Site | Winter Park | Florida | — | — |
| 205.372.01045 Boehringer Ingelheim Investigational Site | Calhoun | Georgia | — | — |
| 205.372.01043 Boehringer Ingelheim Investigational Site | Normal | Illinois | — | — |
| 205.372.01061 Boehringer Ingelheim Investigational Site | Dubuque | Iowa | — | — |
| 205.372.01035 Boehringer Ingelheim Investigational Site | Wichita | Kansas | — | — |
| 205.372.01049 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 205.372.01015 Boehringer Ingelheim Investigational Site | Biddeford | Maine | — | — |
| 205.372.01067 Boehringer Ingelheim Investigational Site | Columbia | Maryland | — | — |
| 205.372.01006 Boehringer Ingelheim Investigational Site | Rockville | Maryland | — | — |
| 205.372.01013 Boehringer Ingelheim Investigational Site | Detroit | Michigan | — | — |
| 205.372.01003 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 205.372.01021 Boehringer Ingelheim Investigational Site | Chesterfield | Missouri | — | — |
| 205.372.01014 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 205.372.01036 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 205.372.01046 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 205.372.01024 Boehringer Ingelheim Investigational Site | Mineola | New York | — | — |
| 205.372.01029 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 205.372.01030 Boehringer Ingelheim Investigational Site | Syracuse | New York | — | — |
| 205.372.01026 Boehringer Ingelheim Investigational Site | Chapel Hill | North Carolina | — | — |
| 205.372.01019 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 205.372.01027 Boehringer Ingelheim Investigational Site | Elizabeth City | North Carolina | — | — |
| 205.372.01038 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 205.372.01031 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 205.372.01017 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.372.01041 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.372.01044 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.372.01001 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 205.372.01063 Boehringer Ingelheim Investigational Site | Eugene | Oregon | — | — |
| 205.372.01068 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 205.372.01056 Boehringer Ingelheim Investigational Site | Swathmore | Pennsylvania | — | — |
| 205.372.01039 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 205.372.01050 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 205.372.01005 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 205.372.01018 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 205.372.01040 Boehringer Ingelheim Investigational Site | New Braunfels | Texas | — | — |
| 205.372.01052 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 205.372.01022 Boehringer Ingelheim Investigational Site | Danville | Virginia | — | — |
| 205.372.01065 Boehringer Ingelheim Investigational Site | Lynchburg | Virginia | — | — |
| 205.372.01055 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 205.372.01064 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 277 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00387088, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 16, 2014 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00387088 live on ClinicalTrials.gov.